Tuesday, July 13th: AFLB (A5 Laboratories Inc.) was just posted as our Biotech Breakthrough Pick.
This one could be very huge and it is just beginning its takeoff. We believe it could be our next monster mover.
We believe Wednesday is an unbelievable opportunity for those who know about AFLB! Investors are coming onto AFLB quickly.
A5 Laboratories Inc.
Symbol: AFLB
Current Price: $0.95
Snapshot - "AFLB is just beginning its takeoff and we believe AFLB could become our next monster play. AFLB has trended higher the past three trading days from a low of $0.80 last Friday to closing at its high of $0.95 during Tuesday's (7/13) trading day. This stock is moving in the right direction and just announced breakthrough news. On Monday, AFLB completed the acquisition of biotech assets from a group called Contract Research. This all comes as AFLB has seen significantly increased attention the past seven trading days. We have a feeling AFLB is about to receive a lot more attention in the coming trading days. Investors are getting in at the ground floor and its moving quickly! Wednesday (7/14) is an unbelievable opportunity to get positioned into AFLB."
We predict that AFLB could become one of our biggest biotech winners of all-time.
It is early in the game and we see this stock going much higher. It is so new that investors are just discovering it and we believe as people discover it, we'll see it trading at a higher level. We believe AFLB, right now, is at an incredible entry price level.
We believe we could see an eye opening breakout in AFLB shares. With the acquisition of Contract Research, AFLB now has the assets at their disposal to develop and commercialize novel biotechnology products.
Within their new asset purchase is Interferon production technology. Interferon's can inhibit viruses from spreading to neighboring cells and it can aid in destroying cancerous cells.
Commercialization of Interferon is ground breaking including treatment for viral infections such as hepatitis C and as a treatment for certain cancers.
We believe the Contract Research acquisition has yet to be priced into AFLB, but it is becoming priced in quickly! We believe there is a remarkable amount of room for AFLB shares to see strong price appreciation.
With the Contract Research acquisition, AFLB has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector.
AFLB is just starting to move, so research it as soon as possible. Wednesday is a prime opportunity to get in on AFLB!
